NASDAQ : ANIP
ANI Pharmaceuticals, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 72 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.54B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.51B |
| Enterprise Value | 1.76B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 21.43M |
| Shares Outstanding | 21.43M |
| Shares Change (YoY) | +12.56% |
| Shares Change (QoQ) | +1.72% |
| Owned by Insiders (%) | 6.14% |
| Owned by Institutions (%) | 115.21% |
| Float | 19.67M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 15.57 |
| Forward PE | 7.72 |
| PS Ratio | 1.55 |
| Forward PS | 1.30 |
| PB Ratio | 2.54 |
| P/TBV Ratio | 17.84 |
| P/FCF Ratio | 8.75 |
| P/OCF Ratio | 7.99 |
| PEG Ratio | 1.93 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 17.71 |
| EV / Sales | 1.80 |
| EV / EBITDA | 8.42 |
| EV / EBIT | 14.27 |
| EV / FCF | 10.19 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.91 |
| Quick Ratio | 2.30 |
| Debt / Equity | 1.05 |
| Debt / EBITDA | 2.93 |
| Debt / FCF | 3.62 |
| Interest Coverage | 4.00 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 20.46% |
| Return on Assets (ROA) | 5.45% |
| Return on Invested Capital (ROIC) | 10.96% |
| Return on Capital Employed (ROCE) | 10.21% |
| Weighted Average Cost of Capital (WACC) | 6.03% |
| Revenue Per Employee | $1.01M |
| Profits Per Employee | $102,677 |
| Employee Count | 970 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.75 |
Taxes
| Measure | Value |
|---|
| Income Tax | 34.29M |
| Effective Tax Rate | 24.04% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -22.00% |
| 50-Day Moving Average | 72.86 |
| 200-Day Moving Average | 77.58 |
| Relative Strength Index (RSI) | 42.59 |
| Average Volume (20 Days) | 336,812 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.47M |
| Short Previous Month | 3.49M |
| Short % of Shares Out | 16.20% |
| Short % of Float | 17.65% |
| Short Ratio (days to cover) | 8.21 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 978.38M |
| Gross Profit | 590.98M |
| Operating Income | 123.60M |
| Pretax Income | 142.60M |
| Net Income | 99.60M |
| EBITDA | 209.41M |
| EBIT | 123.60M |
| Earnings Per Share (EPS) | $4.54 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 376.96M |
| Total Debt | 626.03M |
| Net Cash | -249.07M |
| Net Cash Per Share | -$11.62 |
| Equity (Book Value) | 597.21M |
| Book Value Per Share | 27.87 |
| Working Capital | 541.78M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 189.47M |
| Capital Expenditures | -16.48M |
| Depreciation & Amortization | 85.80M |
| Net Borrowing | -14.22M |
| Free Cash Flow | 172.99M |
| FCF Per Share | $8.07 |
Margins
| Measure | Value |
|---|
| Gross Margin | 60.40% |
| Operating Margin | 12.63% |
| Pretax Margin | 14.57% |
| Profit Margin | 11.07% |
| EBITDA Margin | 21.40% |
| EBIT Margin | 12.63% |
| FCF Margin | 17.68% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.56% |
| Shareholder Yield | -12.56% |
| Earnings Yield | 6.42% |
| FCF Yield | 11.42% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $105.78 |
| Price Target Difference | 49.68% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 14.40% |
| EPS Growth Forecast (3Y) | 13.63% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 18, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.53 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |